首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL-31 |
| Uniprot No | Q6EBC2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-164aa |
| 氨基酸序列 | LPVRLLRPSD DVQKIVEELQ SLSKMLLKDV EEEKGVLVSQ NYTLPCLSPD AQPPNNIHSP AIRAYLKTIR QLDNKSVIDE IIEHLDKLIF QDAPETNISV PTDTHECKRF ILTISQQFSE CMDLALKSLT SGAQQATT |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于IL-31重组蛋白的参考文献及简要摘要概括：
---
1. **文献名称**: *"Interleukin 31. a cytokine produced by activated T cells, induces dermatitis in mice"*
**作者**: Dillon SR, et al.
**摘要**: 首次报道IL-31重组蛋白的克隆与功能，发现IL-31由活化T细胞分泌，通过结合受体IL-31RA/OSMRβ复合物引发小鼠皮肤炎症和瘙痒，提示其与特应性皮炎等瘙痒性皮肤病的关联。
---
2. **文献名称**: *"IL-31 promotes immune response in human keratinocytes and atopic dermatitis"*
**作者**: Zhang Q, et al.
**摘要**: 研究IL-31重组蛋白对体外培养人角质形成细胞的作用，发现其激活STAT3/STAT5信号通路，上调促炎因子(如CCL2、TSLP)，揭示IL-31在特应性皮炎中促发慢性炎症和皮肤屏障破坏的机制。
---
3. **文献名称**: *"The IL-31/IL-31R axis contributes to neutrophil-mediated inflammation in a murine model of psoriasis"*
**作者**: Bilsborough J, et al.
**摘要**: 通过重组IL-31蛋白处理小鼠模型，证明IL-31通过募集中性粒细胞加剧银屑病样皮肤病变，阻断IL-31信号可减轻炎症，为靶向IL-31治疗炎症性皮肤病提供依据。
---
4. **文献名称**: *"Anti-IL-31 receptor antibody improves atopic dermatitis-like symptoms by suppressing sensory neuron activation"*
**作者**: Guttman-Yassky E, et al.
**摘要**: 临床试验显示，抗IL-31受体单抗可显著缓解特应性皮炎患者的瘙痒和皮损，机制研究表明IL-31重组蛋白直接激活感觉神经元，提示其介导瘙痒的神经免疫交叉作用。
---
以上文献涵盖IL-31的分子机制、疾病关联及治疗应用方向。如需具体期刊或年份，可补充说明。
Interleukin-31 (IL-31) is a cytokine primarily associated with inflammatory and pruritic (itch-inducing) responses, particularly in skin disorders. Produced mainly by activated T-helper type 2 (Th2) cells, IL-31 signals through a heterodimeric receptor composed of IL-31 receptor alpha (IL-31RA) and oncostatin M receptor beta (OSMRβ). This interaction activates JAK/STAT, MAPK, and PI3K/AKT signaling pathways, driving itch sensation, epidermal barrier dysfunction, and immune cell recruitment. Its role in chronic pruritic conditions, such as atopic dermatitis (AD), has made IL-31 a key therapeutic target.
Recombinant IL-31 proteins are engineered using expression systems like *E. coli* or mammalian cells to mimic native IL-31 activity for research and drug development. These proteins typically include tags (e.g., His-tag) for purification and are characterized via SDS-PAGE, Western blot, and bioassays to ensure functionality. In preclinical studies, recombinant IL-31 induces scratching behavior in mice, aiding mechanistic studies of itch pathways. Conversely, IL-31 inhibitors, such as nemolizumab (anti-IL-31RA antibody), have shown efficacy in clinical trials for AD, underscoring IL-31's translational relevance.
Beyond dermatology, IL-31 is implicated in allergic asthma, fibrosis, and autoimmune diseases, though its broader physiological roles remain under investigation. Recombinant IL-31 tools continue to advance our understanding of immune-mediated itch and inflammation, bridging basic research to therapeutic innovation.
×
